Enzymatica AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENZY.ST research report →
Companywww.enzymatica.se
Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme mouth spray, which prevents common cold and reduces the duration of illness. It also provides enzyme formulations.
- CEO
- Sana Alajmovic
- IPO
- 2011
- Employees
- 21
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $575.28M
- P/E
- -12.15
- P/S
- 10.84
- P/B
- 5.19
- EV/EBITDA
- -11.45
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 58.61%
- Op Margin
- -89.86%
- Net Margin
- -89.21%
- ROE
- -36.81%
- ROIC
- -42.75%
Growth & Income
- Revenue
- $53.90M · 18.27%
- Net Income
- $-51,890,000 · 2.42%
- EPS
- $-0.21 · 25.00%
- Op Income
- $-52,208,000
- FCF YoY
- 32.34%
Performance & Tape
- 52W High
- $3.40
- 52W Low
- $1.60
- 50D MA
- $2.65
- 200D MA
- $2.20
- Beta
- -0.37
- Avg Volume
- 112.12K
Get TickerSpark's AI analysis on ENZY.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ENZY.ST Coverage
We haven't published any research on ENZY.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ENZY.ST Report →